René Raavé studied biomedical sciences at the Radboud university medical center. He graduated in toxicology and human pathobiology in 2012. After his MSc graduation he received a 228,000 Euro individual 4-year PhD grant which enabled him to start with his PhD-project at the department of Biochemistry. His PhD project focused on the development of a drug delivery system for ovarian cancer treatment. In 2017 he started as a postdoc at the department of Radiology and Nuclear Medicine. In the Nuclear Medicine group he works on the EU TRISTAN project in which novel zirconium chelators are evaluated for their suitability for in vivo biodistribution studies.